Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

20211,542 citationsJournal Articlegreen Open Access

Authors

Stephen J. Thomas · Johns Hopkins University

Edson D. Moreira · Johns Hopkins University

Nicholas Kitchin · Johns Hopkins University

Judith Absalon · Johns Hopkins University

Alejandra Gurtman · Johns Hopkins University

Stephen Lockhart · Johns Hopkins University

John L. Perez · Johns Hopkins University

Gonzalo Pérez Marc

Abstract

Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Viral Infections and Immunology Research Immune responses and vaccinations

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 19, pp. 1761-1773

DOI: 10.1056/nejmoa2110345

Field-Weighted Citation Impact: 90.32

Command Palette

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Authors

Abstract

Topics & Keywords

Publication Details